OKUR übertreffen die 11 der letzten 19Schätzungen.
58%
Nächster Bericht
Datum des nächsten Berichts
09. März 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$1.17
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
+7.34%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-14.60%
OnKure Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On 06. Nov. 2025, OKUR reported earnings of -1.09 USD per share (EPS) for Q3 25, beating the estimate of -1.22 USD, resulting in a 10.80% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.96% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -1.17 USD, with revenue projected to reach -- USD, implying an increase of 7.34% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were OnKure Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, OnKure Therapeutics, Inc. Class A Common Stock reported EPS of -$1.09, beating estimates by 10.8%, and revenue of $0.00, 0% as expectations.
How did the market react to OnKure Therapeutics, Inc. Class A Common Stock's Q3 2025 earnings?
The stock price moved down -6.96%, changed from $3.16 before the earnings release to $2.94 the day after.
When is OnKure Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for 09. März 2026.
What are the forecasts for OnKure Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on 7
analysts, OnKure Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$1.17 and revenue of -- for Q4 2025.